A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test

Exclusion Criteria

• •Patients with any of the following criteria will not be included in the trial:
• •1 Patients with a past history of allergy to this type of reagent;
• •2 Patients with a history of heart disease who are difficult to adapt to bronchial provocation test;
• •3 Patients who have undergone thoracic or abdominal surgery within 6 months before the trial;
• •4 Patients who have undergone surgery for intracranial, ophthalmic diseases, ear, nose and throat diseases, and respiratory diseases 6 months before the trial;
• •5 Complicated pneumothorax and other respiratory diseases or tuberculosis and other infectious diseases;
• •6 Patients with diseases that may be affected by the use of cholinergic drugs (epilepsy, bradycardia, coronary artery occlusion, vagal tension, thyroid disease, arrhythmia, peptic ulcer, urinary tract disorders, etc.);
• •7 Patients with a past history of drug dependence or alcohol dependence;
• •8 Previous severe circulatory system diseases, hepatobiliary system diseases, digestive tract diseases, urinary system diseases, kidney diseases, blood diseases, endocrine system diseases, immune system diseases, malignant tumors, etc.;
• •9 Patients who are using cholinase inhibitors (treatment of myasthenia gravis);
• •10 Patients with unexplained urticaria;
• •11 Pregnant and lactating women;
• •12 Subjects with dyspnea, wheezing, wheezing on the day of the trial;
• •13 Patients with myocardial infarction or stroke, combined with hypertension (systolic blood pressure \> 200 mmHg, diastolic blood pressure \> 100 mmHg);
• •14 Poor cooperation in basic pulmonary function tests, not in line with quality control;
• •15 Use of drugs that will affect airway systolic function and airway inflammation, thereby affecting airway reactivity and can not be discontinued before the test (bronchodilator drugs, glucocorticoids, anti-allergic drugs and triene receptor antagonists and others);
• •16 Current smokers, those who quit for less than one year at the time of screening, and those with a smoking history of more than 10 packs/year;
• •17 Abnormalities in physical examination, laboratory tests, vital signs and test-related tests are clinically significant (based on clinician judgment);
• •18 The investigators think that there are any unsuitable for inclusion;
• •Patients with asthma:
• •1 Hospitalized for asthma exacerbation within 12 weeks;
• •2 Patients with combined respiratory diseases (such as COPD, etc.) that may affect the efficacy and safety evaluation of the drug;
• •Healthy subjects:
• •1 Have used any drugs in 2 weeks;
• •2 Patients, immediate family members suffering from allergic diseases (allergic rhinitis, specific rhinitis, allergic conjunctivitis, chronic urticaria, food allergy, etc.);
• •3 Patients with upper respiratory tract infection, acute sinusitis and other infection-related symptoms or have received treatment in 6 weeks.